# Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed)

Source: https://welltoldgrants.com/grants/par-23-169-innovation-for-hiv-vaccine-discovery-r01-clinical-trial/  
Official notice: https://www.grants.gov/search-results-detail/347659

> National Institutes of Health offered grants of up to $350,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on May 23, 2025.

| Field | Value |
|---|---|
| Opportunity number | PAR-23-169 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | May 23, 2025 |
| Award ceiling | $350,000 |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.855 |

## Who can apply

- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

## What the grant funds

The purpose of this reissued Funding Opportunity Announcement (FOA) is to support high-risk, high-impact, early discovery research on vaccine approaches to prevent acquisition of or ongoing infection by HIV. In keeping with the high-risk, high-impact nature of this research, this FOA supports a Go/No-Go approach to funding high risk research, which is significantly different from most R01 projects. Continued funding for the full award duration is dependent upon achieving negotiated Go/No-Go criteria by the end of Year 2.

## Questions people ask

### Is PAR-23-169 still open?

No. It closed on May 23, 2025.

### Who can apply for Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed)?

National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed)?

Closed May 23, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

Awards of up to $350,000 each.

### Who has been funded under PAR-23-169?

NIH RePORTER lists 4 projects funded under PAR-23-169 in fiscal 2024 to 2026, at 4 institutions. The most were at Fred Hutchinson Cancer Center, The Scripps Research Institute, University of Pennsylvania.

### Who has won Allergy and Infectious Diseases Research grants before?

The largest recipients over five fiscal years were Fred Hutchinson Cancer Center, Duke University, University of California, Los Angeles. The program made 13,282 awards worth $22 billion in that time.